Dyne Therapeutics (DYN) Enterprise Value (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Enterprise Value data on file, last reported at -$972.2 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 43.49% year-over-year to -$972.2 million in Q1 2026; TTM through Mar 2026 was -$972.2 million, a 43.49% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 billion, down 72.91% from the prior year.
• Enterprise Value for Q1 2026 stood at -$972.2 million, up from -$1.1 billion in the prior quarter.
• Over the last five years, Enterprise Value for DYN reached as high as -$123.1 million in Q4 2023 and fell as low as -$1.1 billion in Q4 2025.
• Historically, Enterprise Value has averaged -$505.5 million across 5 years, with a median of -$453.5 million in 2024.
• Across the five-year window, Enterprise Value surged 51.92% in 2023 and tumbled 421.74% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$256.0 million in 2022, then jumped by 51.92% to -$123.1 million in 2023, then tumbled by 421.74% to -$642.3 million in 2024, then sank by 72.91% to -$1.1 billion in 2025, then advanced by 12.46% to -$972.2 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$972.2 million in Q1 2026, -$1.1 billion in Q4 2025, and -$791.9 million in Q3 2025.